Spray drying of a poorly water-soluble drug nanosuspension for tablet preparation: Formulation and process optimization with bioavailability evaluation

Drug Development and Industrial Pharmacy

Volumn 41, Issue 6, 2015, Pages 927-933

  Sun, Wei ^a   Ni, Rui ^a   Zhang, Xin ^a   Li, Luk Chiu ^b   Mao, Shirui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Itraconazole; Micrometric properties; Nanocrystal; Nanosuspension; Spray drying

Indexed keywords

EXCIPIENT; ITRACONAZOLE; MANNITOL; NANOCRYSTAL; ANTIFUNGAL AGENT; NANOPARTICLE; POWDER; TABLET; WATER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BEAGLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRY POWDER; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; POWDER FLOW; PROCESS OPTIMIZATION; SPRAY DRYING; TABLET; TABLET COMPRESSION; TABLET FORMULATION; TEMPERATURE; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY DIFFRACTION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; COMPARATIVE STUDY; CRYSTALLIZATION; DOG; FEASIBILITY STUDY; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; POWDER; PROCEDURES; SOLUBILITY;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DOGS; EXCIPIENTS; FEASIBILITY STUDIES; ITRACONAZOLE; MALE; MANNITOL; NANOPARTICLES; PARTICLE SIZE; POWDERS; SOLUBILITY; TABLETS; WATER; X-RAY DIFFRACTION;

EID: 84930510224     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2014.914528     Document Type: Article

References (24)

1. Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev 2011;63:427-40.
2. Kesisoglou F, Panmai S, Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007;59:631-44.
3. Lai F, Sinico C, Ennas G, et al. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour. Int J Pharm 2009;373:124-32.
4. Mauludin R, Müller RH, Keck CM. Development of an oral rutin nanocrystal formulation. Int J Pharm 2009;370:202-9.
5. Verma S, Lan Y, Gokhale R, Burgess DJ. Quality by design approach to understand the process of nanosuspension preparation. Int J Pharm 2009;377:185-98.
6. Van Eerdenbrugh B, Van Den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization, and transformation into solid products. Int J Pharm 2008;364:64-75.
7. Ain-Ai A, Gupta PK. Effect of arginine hydrochloride and hydroxypropyl cellulose as stabilizers on the physical stability of high drug loading nanosuspensions of a poorly soluble compound. Int J Pharm 2008;351:282-8.
8. Kumar MP, Rao YM, Apte S. Formulation of nanosuspensions of albendazole for oral administration. Curr Nanosci 2008;4:53-8.
9. Zhang D, Tan T, Gao L, et al. Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev Ind Pharm 2007;33: 569-75.
10. Xu D, Ni R, Sun W, et al. In vivo absorption comparison of nanotechnology-based silybin tablets with its water-soluble derivative. Drug Dev Ind Pharm 2014. [Epub ahead of print].
11. Ho H, Lee J. Redispersible drug nanoparticles prepared without dispersant by electro-spray drying. Drug Dev Ind Pharm 2012;38: 744-51.
12. Sun W, Mao S, Shi Y, et al. Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption. J Pharm Sci 2011;100:3365-73.
13. Sun W, Tian W, Zhang Y, et al. Effect of novel stabilizers-cationic polymers on the particle size and physical stability of poorly soluble drug nanocrystals. Nanomedicine NBM 2012;8:460-7.
14. Podczeck F, Jones BE. Pharmaceutical capsules. London, UK: Pharmaceutical Press; 2004.
15. Jung H, Kim H, Choy YB, et al. Laponite based nanohybrid for enhanced solubility and controlled release of itraconazole. Int J Pharm 2008;349:283-90.
16. Zhang T, Mao S, Sun W. Design and in vitro evaluation of a filmcontrolled dosage form self-converted from monolithic tablet in gastrointestinal environment. J Pharm Sci 2012;99:4678-90.
17. Tomoda K, Ohkoshi T, Kawai Y, et al. Preparation and properties of inhalable nanocomposite particles: effects of the temperature at a spray-dryer inlet upon the properties of particles. Colloids Surf B Biointerfaces 2008;61:138-44.
18. Gao Y, Li Z, Sun M, et al. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. Drug Dev Ind Pharm 2010;36:1225-34.
19. Patel GV, Patel VB, Pathak A, Rajput SJ. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation. Drug Dev Ind Pharm 2014;40:80-91.
20. Kawashima Y, Imai M, Takeuchi H, et al. Improved flowability and compactibility of spherically agglomerated crystals of ascorbic acid for direct tableting designed by spherical crystallization process. Powder Technol 2003;130:283-9.
21. Gohel MC, Jogani PD. Functionality testing of a multifunctional directly compressible adjuvant containing lactose, polyvinylpyrrolidone, and croscarmellose sodium. Pharm Technol 2002;26: 64-82.
22. Dürig T, Fassihi R. Mechanistic evaluation of binary effects of magnesium stearate and talc as dissolution retardants at 85% drug loading in an experimental extended-release formulation. J Pharm Sci 1997;86:1092-8.
23. Sun C, Grant DJW. Effects of initial particle size on the tableting properties of L-lysine monohydrochloride dihydrate powder. Int J Pharm 2001;215:221-8.
24. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy-rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47: 3-19.